Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liarozole in Lamellar Ichthyosis
NCT00282724Phase 3Completed
- Sponsor
- GSK
- Start
- Jan 2006
- Primary completion
- Apr 2007
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 3, randomised, double-blind trial of Liarozole in lamellar ichthyosis (LI) (3 arms), sponsored by GSK. Primary endpoint: Investigator's Global Assessment Response Rate at 12 weeks. Started Jan 2006; status: completed.
02
Drugs
Liarozole
03
Conditions
lamellar ichthyosis (LI)
Beyond the preview
Go deeper on NCT00282724.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00282724.